Figure 4

Recurrence-free survival (RFS) according to (a) histological subtype, (b) differentiation, (c) CDK4 amplification, (d) JUN amplification, (e) 5′-UTR and exons 1–3 amplification of HMGA2, and (f) 3′-UTR amplification of HMGA2. ALT/WDLPS, atypical lipomatous tumor/well-differentiated liposarcoma; DDLPS, dedifferentiated liposarcoma; UTR, untranslated region.